Sign in
Taking people in United StatesPhase 2

Spinal stimulation with or without 5-Azacitidine to help movement in children with cerebral palsy

Tests spinal stimulation, and 5-Azacitidine added to it, for mobility in children with cerebral palsy.

Key facts

Who runs it
Shirley Ryan AbilityLab
Where
Chicago, United StatesSee the site
Trial code
Registry title
tSCS and 5-Azacitidine for Enhanced Motor Outcomes in Cerebral Palsy
Status
Recruiting
Phase
Phase 2
People taking part
80 people, planned
Started
28 May 2026
Expected to end
31 Aug 2030
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • tSCS
  • 5-Azacitidine
  • Mannitol
  • Functional Activity Training
Record updated
5 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children aged 4 to 17 with spastic cerebral palsy. They will do 16 weeks of spinal stimulation through the skin with walking or activity training. Some may choose to also get a 5-Azacitidine or placebo injection.

Age
4 to 17 years
Sex
All sexes
Disease stage
Spastic cerebral palsy (hemiplegia, diplegia or quadriplegia), GMFCS Levels I-V. The child's health must be stable. The child must follow 2-3 step commands, answer yes or no, and show where pain is.
Earlier treatment
No orthopedic surgery in the prior 12 months. No Botulinum toxin within 3 months before joining, unless the treating doctor approves. No implanted stimulator or drug pump (e.g., baclofen pump).

Main reasons for not taking part

  • Another disease of the brain or spinal cord, or uncontrolled seizures
  • Implanted devices (e.g., pacemaker, cochlear implant), or needing breathing support
  • Unhealed fracture, or bone, joint, heart or muscle problems that would limit training
  • Active cancer or cancer in remission less than 5 years, or immune or blood conditions
  • Pregnancy, allergy to AZA or mannitol, or a vaccine planned within 30 days of the week 10 injection

The registry criteria, word for word

Show all 32 criteriaShow less

Who can take part

  • Diagnosis of cerebral palsy (CP) classified as Gross Motor Function Classification System (GMFCS) Levels I-V
  • Between 4 and 17 years old at the time of enrollment/consent
  • Diagnosis of spastic CP hemiplegia, diplegia, or quadriplegia
  • Stable medical condition as determined by the investigator
  • Adequate caregiver support to be able to participate in training and assessment sessions for the duration of the study, at the discretion of the Investigator
  • Capable of performing simple cued motor tasks and can follow 2-3 step commands
  • Capable of communicating an accurate yes or no answer to questions according to parent or guardian
  • Able to localize pain/ discomfort
  • Physician approval for participation
  • Parent/ guardian permission

Who cannot take part

  • Concurrent neurological disease affecting the central nervous system
  • Orthopedic dysfunction, injury, or surgery that would impact an individual's ability to use the upper and/or lower extremity
  • Implanted stimulator (e.g., epidural stimulator, vagus nerve stimulator, pacemaker, cochlear implant) or drug delivery device (e.g., baclofen pump)
  • Plans to receive a vaccine within 30 days of the planned AZA or placebo injection to take place at week 10
  • Orthopedic surgery completed in the prior 12 months
  • Intrathecal medication titration that may affect muscle spasticity
  • Cardiovascular or musculoskeletal disease or injury that would prevent full participation in physical therapy intervention
  • Unhealed fracture or other musculoskeletal impairment that might interfere with upper or lower extremity rehabilitation or testing activities
  • Dependence on an electro-magnetic medical implant (e.g., cardiac pacemaker, implanted drug pump), ventilation support, or another external device
  • History of uncontrolled seizures
  • Severe cortico-visual impairment
  • Active cancer or cancer in remission less than 5 years
  • Clinically significant depression, psychiatric disorders, or ongoing drug abuse
  • Immunodeficiency or hematologic condition
  • Allergy to AZA or mannitol
  • Any other health condition or diagnosis not listed above that may put the participant at risk as determined by the investigator or treating physician
  • Unexplained presence of persistent complaints of pain of any kind
  • Unable to localize pain/discomfort
  • Active pressure sores
  • Pregnancy
  • Botulinum toxin treatment within 3 months preceding enrollment unless given approval by the treating physician
  • Current enrollment in a conflicting research study

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 4 and 17 years old?

Where in United States

  • Shirley Ryan AbilityLabChicago, United StatesContact: Arun Jayaraman, PhD (principal investigator)Taking people

About the trial

What the trial wants to find out

This is an intervention study to investigate the impact of spinal stimulation on mobility outcomes in children with Cerebral Palsy. Participants will complete a 16-week training program with weekly sessions of spinal stimulation and walking or activity-based training. Participants will also have the option to participate in a randomized control trial to investigate the impact of 5-Azacitidine combined with the spinal stimulation to further affect mobility outcomes.

The 3 groups in the trial

  • tSCS + Functional Activity TrainingExisting treatment, for comparison

    Transcutaneous spinal cord stimulation will be paired with training based on Aim. Participants in Aim 1(GMFCS levels 1-3) will engage in three sessions a week for 16 weeks of treadmill and overground gait training using tSCS. Participants in Aim 2(GMFCS levels 4-5) will engage in three sessions a week for 16 weeks of functional activity based training as appropriate.

    Treatment: tSCS and Functional Activity Training

  • tSCS + Functional Activity Training + 5-AzacitidineTreatment being tested

    Transcutaneous spinal cord stimulation will be paired with training based on Aim. Participants in Aim 1(GMFCS levels 1-3) will engage in three sessions a week for 16 weeks of treadmill and overground gait training using tSCS. Participants in Aim 2(GMFCS levels 4-5) will engage in three sessions a week for 16 weeks of functional activity based training as appropriate. A subset of opt-in participants will also be randomized to receive either 5-Azacitidine (VIDAZA) or placebo (Mannitol) at midpoint. A registered nurse will deliver a single subcutaneous injection of either AZA or placebo at a dose of 75 mg/m² to the participants lower abdomen or medial thigh.

    Treatment: tSCS, 5-Azacitidine, and Functional Activity Training

  • tSCS + Functional Activity Training + Mannitol (Placebo)Existing treatment, for comparison

    Transcutaneous spinal cord stimulation will be paired with training based on Aim. Participants in Aim 1(GMFCS levels 1-3) will engage in three sessions a week for 16 weeks of treadmill and overground gait training using tSCS. Participants in Aim 2(GMFCS levels 4-5) will engage in three sessions a week for 16 weeks of functional activity based training as appropriate. A subset of opt-in participants will also be randomized to receive either 5-Azacitidine (VIDAZA) or placebo (Mannitol) at midpoint. A registered nurse will deliver a single subcutaneous injection of either AZA or placebo at a dose of 75 mg/m² to the participants lower abdomen or medial thigh.

    Treatment: tSCS, Mannitol, and Functional Activity Training

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Advancing Neurorehabilitation: Evaluating Transcutaneous Spinal Stimulation and 5-Azacitidine for Enhanced Motor Outcomes in Cerebral Palsy
Plain-language title
Spinal stimulation with or without 5-Azacitidine to help movement in children with cerebral palsyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07433023, who can take part
Record updated
5 November 2026